# Vertex Pharmaceuticals Incorporated – Consensus ‘buy’ rating and 10.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-consensus-buy-rating-and-10-8-upside-potential/4121185468
- Published: 2025-01-31T12:04:25+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 29 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $591.00 and $330.00 suggesting an average
Analsyt target price of $489.32. Given that the stocks previous close was at $441.52
this is indicating there is a potential upside of 10.8%. There is a 50 day moving
average of $438.71 and the 200 day MA is $458.47. The company has a market cap of
112.90B. The current share price for the company is: $438.40 USD

 The potential market cap would be $125,123,258,151 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $41.19 and
a 12.05% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on:
